Industry
Biotechnology
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Loading...
Open
1.15
Mkt cap
364K
Volume
265K
High
1.16
P/E Ratio
-0.01
52-wk high
898.00
Low
1.09
Div yield
N/A
52-wk low
1.08
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 12:34 pm
Portfolio Pulse from Avi Kapoor
October 28, 2024 | 10:32 am
Portfolio Pulse from Benzinga Newsdesk
October 25, 2024 | 1:51 pm
Portfolio Pulse from Benzinga Newsdesk
October 25, 2024 | 1:47 pm
Portfolio Pulse from Benzinga Newsdesk
October 25, 2024 | 1:46 pm
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 12:48 pm
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 12:38 pm
Portfolio Pulse from Benzinga Insights
October 22, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Insights
October 22, 2024 | 12:07 pm
Portfolio Pulse from Avi Kapoor
October 22, 2024 | 11:06 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.